W. Jean Dodds has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Elizabeth Carney

    Peaceful Pet Passages, York, PA, USA

    1 shared publication
  • Herbert A. Fritsche

    Aspira Women's Health, Trumbull, CT

    1 shared publication
  • Jaclyn Jeffrey

    Allegiant, Weston, CT, USA

    1 shared publication
  • Jon P. Kimball

    The Potter-Hawkins Group LLC, Chapel Hill, NC, USA

    1 shared publication
  • Judy Morgan

    Dr. Judy Morgan's Naturally Healthy Pets, Woodstown, NJ, USA

    1 shared publication
  • Kris L. Christine

    Hemopet, 11561 Salinaz Avenue, Garden Grove, California 92843, USA (Dodds); Department of Pathobiological Sciences, School of Veterinary Medicine, 2015 Linden Drive West, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA [Larson, Schultz (Emeritus)]; Christine Road, Alna, Maine 04535, USA (Christine)

    1 shared publication

Latest Publications

  • Open Access

    Review of: "Critique of "First quantitative assessment of the effects of parasite control in dogs and cats in the UK": Re-examining Parasiticide-Industry-Funded Estimates of Parasite-Control Benefits in UK Dogs and Cats"

    by W. Jean Dodds

    This critique of Giannelli et al. (Parasites & Vectors 18:498, 2025 https://link.springer.com/article/10.1186/s13071-025-07137-8) is important and correct, in my opinion. As restated here, the CONCLUSIONS are correct and well documented in the Refe...

  • Open Access

    Review of: "RNA in-situ hybridization for pathology-based diagnosis of feline infectious peritonitis (FIP): current diagnostics for FIP and comparison to the current gold standard"

    by W. Jean Dodds

    No potential competing interests to declare. This revised manuscript is excellent and has answered prior comments by the reviewers.

  • Open Access

    One Health: Animal Models of Heritable Human Bleeding Diseases

    by W. Jean Dodds

    Animal models of human and animal diseases have long been used as the lynchpin of experimental and clinical research. With the discovery and implementation of novel molecular and nano-technologies, cellular research now has advanced to assessing signal transduction pathways, gene editing, and gene therapies. The contribution of heritable animal models to human and animal health as related to hemostasis is reviewed and updated with the advent of gene editing, recombinant and gene therapies.


  • Open Access

    Early Life Vaccination of Companion Animal Pets

    by W. Jean Dodds

    Development of the immune system of mammalian animal species parallels that of humans and involves the innate and adaptive (acquired) immune responses acting together with the thymus gland. Consequently, issues surrounding the adequacy and safety of vaccinations to protect pet animals from their relevant infectious diseases need to be addressed just as they are for humans. Pet animals, especially canines, also have unique needs because of the wide diversity of purebred and mixed breeds that vary greatly in size, type, temperament, and even maturation rates. Furthermore, pets in early life encounter a series of changes that can affect their development and induce stressors including parasite control, new homes and environment, novel foods, and the socialization that is essential at a time when vaccinations need to be given. While recognizing that this overall need is becoming more understood, current vaccination policy guidelines for companion animals are still only adhered to by about 40% of veterinarians worldwide. Clearly, vaccination of pets should no longer be considered as “one size fits all”.


  • Open Access

    Survey of canine use and safety of isoxazoline parasiticides

    by Valerie Palmieri, W. Jean Dodds, Judy Morgan, Elizabeth Carney, Herbert A. Fritsche, Jaclyn Jeffrey, Rowan Bullock, Jon P. Kimball

    A veterinarian and pet owner survey (Project Jake) examined the use and safety of isoxazoline parasiticides given to dogs. Data were received during August 1–31, 2018 from a total of 2,751 survey responses. Forty‐two percent (1,157) reported no flea treatment or adverse events (AE), while 58% (1594) had been treated with some parasiticide for flea control, and of those that received a parasiticide, the majority, or 83% (1,325), received an isooxazoline. When any flea treatment was given, AE were reported for 66.6% of respondents, with no apparent AE noted for 36.1%. Project Jake findings were compared to a retrospective analysis of publicly available Food and Drug Administration (FDA) and European Medicines Agency (EMA) reported AE. The number of total AE reported to FDA and EMA were comparable, although a 7 to 10 times higher occurrence of death and seizures was reported from the EMA or from outside the United States (US). Serious AE responses for death, seizures and neurological effects reported in our survey were higher than the FDA but moderately lower than the EMA reports. These sizable global data sets combined with this pre‐ and post‐parasiticide administration survey indicated that isoxazoline neurotoxicity was not flea‐ and tick‐specific. Post‐marketing serious AE were much higher than in Investigational New Drug (IND) submissions. Although the labels have recently been updated, dogs, cats and their caregivers remain impacted by their use. These aggregate data reports support the need for continued cross‐species studies and critical review of product labelling by regulatory agencies and manufacturers.


    • 1 April 2020
      • Vol. 84  (2) , 153-158

    Duration of immunity after rabies vaccination in dogs: The Rabies Challenge Fund research study

    by W. Jean Dodds, Laurie J. Larson, Kris L. Christine, Ronald D. Schultz

    A prospective study of 65 research beagles kept in a rabies-free environment was undertaken to determine the duration of immunity after they received licensed rabies vaccines. The eventual goal was to extend mandated rabies booster intervals to 5 or 7 years and help reduce the risk of vaccine-associated adverse events. Three groups of dogs were vaccinated with 1 of 2 commercial rabies vaccines or saline at 12 and 15 weeks of age. Beginning 5 years 5 months later, vaccinated and unvaccinated dogs were challenged with virulent rabies virus and observed for 90 days over a series of 3 trials. Humoral and cellular immune responses were examined by serology and flow cytometry. Brain tissue from all challenged dogs was tested for rabies virus. Challenge trial 1 was confounded due to insufficiently virulent virus. In trials 2 and 3 virulent challenge provided 100% mortality in controls. Vaccinate survival was 80% (4/5) after 6 years 7 months, 50% (6/12) after 7 years 1 month, and 20% (1/5) after 8years 0 months. Antibody responses 12 days post-challenge correlated strongly with survival. In a separate non-challenge trial, administration of either a recombinant or a killed rabies vaccine demonstrated memory antibody responses 6 years 1 month after initial vaccination compared with unvaccinated controls. Our data demonstrated that i) duration of immunity to rabies in vaccinated dogs extends beyond 3 years; ii) immunologic memory exists even in vaccinated dogs with serum antibody titer < 0.1 IU/mL; and iii) non-adjuvanted recombinant rabies vaccine induces excellent antibody responses in previously vaccinated dogs 14 days after administration.


  • Open Access

    Diagnosis of Feline Food Sensitivity and Intolerance Using Saliva: 1000 Cases

    by W. Jean Dodds

    This prospective study assessed the efficacy of a novel saliva-based immunoassay of IgA- and IgM-antibodies in predicting feline food sensitivities and intolerances. Clinical samples were obtained from 1000 cats proven or suspected to have food intolerances. Most were of domestic shorthair breed type, over 10 years of age, and weighed around 5 kg; they were equally distributed between spayed females and neutered males. Saliva was collected after at least an 8-h fast with a dental cotton rope, placed in a double-sleeved saliva collection tube, and sent to the laboratory. Salivary antibodies elicited by 24 common foods were measured with goat anti-canine IgA and IgM. Low reacting foods were lamb, cow milk, pork, turkey, wheat (lowest) and white-colored fish, whereas high reacting foods were millet, white potato, rice (highest) and salmon. Thus, the novel salivary-based food sensitivity and intolerance test, described previously for canines, also provided a reliable and clinically predictive alternative to food elimination trials, serum-based food allergy testing, and skin patch testing in cats. Manufacturers of commercial cat foods and treats, as well as those making homemade diets and treats for cats, should consider avoiding the more highly reactive foods as determined by the present study.